RT Journal Article SR Electronic T1 Mathematical Modeling and Analysis of COVID-19 pandemic in Nigeria JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2020.05.22.20110387 DO 10.1101/2020.05.22.20110387 A1 Enahoro Iboi A1 Oluwaseun O. Sharomi A1 Calistus Ngonghala A1 Abba B. Gumel YR 2020 UL http://medrxiv.org/content/early/2020/07/31/2020.05.22.20110387.abstract AB A novel Coronavirus (COVID-19), caused by SARS-CoV-2, emerged from the Wuhan city of China at the end of 2019, causing devastating public health and socio-economic burden around the world. In the absence of a safe and effective vaccine or antiviral for use in humans, control and mitigation efforts against COVID-19 are focused on using non-pharmaceutical interventions (aimed at reducing community transmission of COVID-19), such as social (physical)-distancing, community lockdown, use of face masks in public, isolation and contact tracing of confirmed cases and quarantine of people suspected of being exposed to COVID-19. We developed a mathematical model for understanding the transmission dynamics and control of COVID-19 in Nigeria, one of the main epicenters of COVID-19 in Africa. Rigorous analysis of the Kermack-McKendrick-type compartmental epidemic model we developed, which takes the form of a deterministic system of nonlinear differential equations, reveal that the model has a continuum of disease-free equilibria which is locally-asymptotically stable whenever a certain epidemiological threshold, called the control reproduction (denoted by ℛc), is less than unity. The epidemiological implication of this result is that the pandemic can be effectively controlled (or even eliminated) in Nigeria if the control strategies implemented can bring (and maintain) the epidemiological threshold (ℛc) to a value less than unity. The model, which was parametrized using COVID-19 data published by Nigeria Centre for Disease Control (NCDC), was used to assess the community-wide impact of various control and mitigation strategies in the entire Nigerian nation, as well as in two states (Kano and Lagos) within the Nigerian federation and the Federal Capital Territory (FCT Abuja). It was shown that, for the worst-case scenario where social-distancing, lockdown and other community transmission reduction measures are not implemented, Nigeria would have recorded a devastatingly high COVID-19 mortality by April 2021 (in hundreds of thousands). It was, however, shown that COVID-19 can be effectively controlled using social-distancing measures provided its effectiveness level is at least moderate. Although the use of face masks in the public can significantly reduce COVID-19 in Nigeria, its use as a sole intervention strategy may fail to lead to the realistic elimination of the disease (since such elimination requires unrealistic high compliance in face mask usage in the public, in the range of 80% to 95%). COVID-19 elimination is feasible in both the entire Nigerian nation, and the States of Kano and Lagos, as well as the FCT, if the public face masks use strategy (using mask with moderate efficacy, and moderate compliance in its usage) is complemented with a social-distancing strategy. The lockdown measures implemented in Nigeria on March 30, 2020 need to be maintained for at least three to four months to lead to the effective containment of COVID-19 outbreaks in the country. Relaxing, or fully lifting, the lockdown measures sooner, in an effort to re-open the economy or the country, may trigger a deadly second wave of the pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementN/AAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A